Medtronic plc today announced the release of outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System in the OPuS One Clinical Study the largest, prospective study in RFA for bone metastases. The study, which is the most meaningful clinical data release for the OsteoCool™ technology to date, showed patients had significant and swift improvement in pain relief at just three … – Medtronic plc (NYSE: MDT) today announced the release of outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation (RFA) System in the OPuS On...